← 返回

一种创新的端粒相关 AML 预后模型:预测免疫浸润和治疗反应

英文原题:An Innovative Telomere-associated Prognosis Model in AML: Predicting Immune Infiltration and Treatment Responsiveness.

查看英文原题

An Innovative Telomere-associated Prognosis Model in AML: Predicting Immune Infiltration and Treatment Responsiveness.

PubMed 2026/01/01(内容时间) Curr Med Chem Q2 · IF 3.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

这种创新的 TRG 评分模型对 AML 患者预后显示出相当大的预测价值,为优化治疗策略和个性化医疗方法提供了有价值的见解。所识别的 TRG 及相关评分模型有助于 AML 患者的风险分层并指导量身定制的治疗干预。

研究思路结论见上方概要

AML是一种高度异质性的恶性血液系统疾病,预后较差。尽管端粒维持现象在肿瘤中常被观察到,但针对AML中端粒相关基因(TRGs)的研究仍然有限。

构建一种创新的端粒相关评分模型,以预测急性髓系白血病(AML)的预后和治疗反应性。本研究旨在利用最小绝对收缩和选择算子(LASSO)Cox回归及多因素Cox回归识别预后TRGs,评估其预测价值,探索TRG评分与免疫细胞浸润之间的关联,并评估高评分AML患者对化疗药物的敏感性。

对TCGA队列进行单因素Cox回归分析,以识别预后TRGs,并使用LASSO-Cox和多因素Cox回归构建TRG评分模型。在GSE37642队列中进行验证。通过计算分析评估免疫细胞浸润模式,并评估对化疗药物的敏感性。

鉴定出13个预后相关TRG,并构建了一个包含7个TRG的评分模型(包括NOP10、OBFC1、PINX1、RPA2、SMG5、MAPKAPK5和SMN1)。较高的TRG评分与较差预后相关,这一点在GSE37642队列中得到证实,并且在调整其他临床特征后仍为独立预后因素。高评分组的特征为B细胞、T辅助细胞、NK 细胞、TIL(肿瘤浸润淋巴细胞)、调节性T(Treg)细胞、M2巨噬细胞、中性粒细胞和单核细胞浸润升高,同时γδT细胞、CD4- T细胞和静息肥大细胞浸润减少。此外,与低浸润相比,M2巨噬细胞和Tregs高浸润与较差的总生存期相关。值得注意的是,高风险AML患者对Erlotinib、Parthenolide和Nutlin-3a耐药,但对AC220、Midostaurin和Tipifarnib敏感。此外,使用RT-qPCR,我们观察到AML组织中两个模型基因OBFC1和SMN1的表达显著高于对照组织。

展开英文摘要原文

AML is a highly heterogeneous malignant hematologic disorder with a poor prognosis. While telomere maintenance is frequently observed in tumors, investigations into telomere-related genes (TRGs) in AML remain limited.

This study aimed to identify prognostic TRGs using the least absolute shrinkage and selection operator (LASSO) Cox regression and multivariate Cox regression, evaluate their predictive value, explore the association between TRG scores and immune cell infiltration, and assess the sensitivity of high-scoring AML patients to chemotherapeutic agents.

Univariate Cox regression analysis was conducted on the TCGA cohort to identify prognostic TRGs and to develop the TRG scoring model using LASSO-Cox and multivariate Cox regression. Validation was performed on the GSE37642 cohort. Immune cell infiltration patterns were assessed through computational analysis, and the sensitivity to chemotherapeutic agents was evaluated.

Thirteen prognostic TRGs were identified, and a seven-TRG scoring model (including NOP10, OBFC1, PINX1, RPA2, SMG5, MAPKAPK5, and SMN1) was developed. Higher TRG scores were associated with a poorer prognosis, as confirmed in the GSE37642 cohort, and remained an independent prognostic factor even after adjusting for other clinical characteristics. The high-score group was characterized by elevated infiltration of B cells, T helper cells, natural killer cells, tumor-infiltrating lymphocytes, regulatory T (Treg) cells, M2 macrophages, neutrophils, and monocytes, along with reduced infiltration of gamma delta T cells, CD4- T cells, and resting mast cells. Moreover, high infiltration of M2 macrophages and Tregs was associated with poor overall survival compared to low infiltration. Notably, high-risk AML patients were resistant to Erlotinib, Parthenolide, and Nutlin-3a, but sensitive to AC220, Midostaurin, and Tipifarnib. Additionally, using RT-qPCR, we observed significantly higher expression of two model genes, OBFC1 and SMN1, in AML tissues compared to control tissues.

This innovative TRG scoring model demonstrates considerable predictive value for AML patient prognosis, offering valuable insights for optimizing treatment strategies and personalized medicine approaches. The identified TRGs and associated scoring models could aid in risk stratification and guide tailored therapeutic interventions in AML patients.

论文信息

作者
Song B、Lou J、Mu L、Lu X、Sun J、Tang B
单位
Department of Hematology, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116023, People's Republic of China.China
期刊
Current medicinal chemistry2026
原文标识
PubMed 39506437 · DOI 10.2174/0109298673334218241021044800